Data Insights

Trastuzumab deruxtecan by Daiichi Sankyo for Metastatic Breast Cancer: Likelihood of Approval

Trastuzumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase III for Metastatic Breast Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Trastuzumab Deruxtecan in Metastatic Breast Cancer

Data Insights

Trastuzumab deruxtecan by Daiichi Sankyo for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval

Trastuzumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase III for Human Epidermal Growth Factor Receptor...

Likelihood of Approval and Phase Transition Success Rate Model - Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)

Data Insights

Trastuzumab deruxtecan by Daiichi Sankyo for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

Trastuzumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According...

Likelihood of Approval and Phase Transition Success Rate Model - Trastuzumab Deruxtecan in Triple-Negative Breast Cancer (TNBC)

Data Insights

Trastuzumab deruxtecan by Daiichi Sankyo for Paget Disease of Bone: Likelihood of Approval

Trastuzumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase I for Paget Disease of Bone. According...

Likelihood of Approval and Phase Transition Success Rate Model - Trastuzumab Deruxtecan in Paget Disease of Bone

Data Insights

Trastuzumab deruxtecan by Daiichi Sankyo for Recurrent Glioblastoma Multiforme (GBM): Likelihood of Approval

Trastuzumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Recurrent Glioblastoma Multiforme (GBM). According...

Likelihood of Approval and Phase Transition Success Rate Model - Trastuzumab Deruxtecan in Recurrent Glioblastoma Multiforme (GBM)

Data Insights

Trastuzumab deruxtecan by Daiichi Sankyo for Esophageal Cancer: Likelihood of Approval

Trastuzumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase I for Esophageal Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Trastuzumab Deruxtecan in Esophageal Cancer

Data Insights

Trastuzumab deruxtecan by Daiichi Sankyo for Breast Cancer: Likelihood of Approval

Trastuzumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Breast Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Trastuzumab Deruxtecan in Breast Cancer

Data Insights

Trastuzumab deruxtecan by Daiichi Sankyo for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval

Trastuzumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma). According...

Likelihood of Approval and Phase Transition Success Rate Model - Trastuzumab Deruxtecan in Bile Duct Cancer (Cholangiocarcinoma)

Data Insights

Trastuzumab deruxtecan by Daiichi Sankyo for Gallbladder Cancer: Likelihood of Approval

Trastuzumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Gallbladder Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Trastuzumab Deruxtecan in Gallbladder Cancer

Data Insights

Trastuzumab deruxtecan by Daiichi Sankyo for Transitional Cell Cancer (Urothelial Cell Cancer): Likelihood of Approval

Trastuzumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Transitional Cell Cancer (Urothelial Cell...

Likelihood of Approval and Phase Transition Success Rate Model - Trastuzumab Deruxtecan in Transitional Cell Cancer (Urothelial Cell Cancer)

Data Insights

Trastuzumab deruxtecan by Daiichi Sankyo for Metastatic Colorectal Cancer: Likelihood of Approval

Trastuzumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Pre-Registration for Metastatic Colorectal Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Trastuzumab Deruxtecan in Metastatic Colorectal Cancer

Data Insights

Trastuzumab deruxtecan by Daiichi Sankyo for Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis): Likelihood of Approval

Trastuzumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal...

Likelihood of Approval and Phase Transition Success Rate Model - Trastuzumab Deruxtecan in Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis)